Stephens Inc. AR Cuts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Stephens Inc. AR trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,990 shares of the biopharmaceutical company’s stock after selling 4,292 shares during the period. Stephens Inc. AR’s holdings in Gilead Sciences were worth $3,140,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Empowered Funds LLC lifted its holdings in shares of Gilead Sciences by 55.8% in the fourth quarter. Empowered Funds LLC now owns 219,579 shares of the biopharmaceutical company’s stock worth $20,283,000 after buying an additional 78,657 shares in the last quarter. Wilmington Savings Fund Society FSB lifted its stake in Gilead Sciences by 6.8% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 19,933 shares of the biopharmaceutical company’s stock worth $1,841,000 after purchasing an additional 1,273 shares in the last quarter. Arlington Financial Advisors LLC boosted its holdings in shares of Gilead Sciences by 2.0% during the 4th quarter. Arlington Financial Advisors LLC now owns 47,020 shares of the biopharmaceutical company’s stock valued at $4,343,000 after purchasing an additional 915 shares during the last quarter. D Orazio & Associates Inc. grew its position in shares of Gilead Sciences by 39.6% during the fourth quarter. D Orazio & Associates Inc. now owns 4,082 shares of the biopharmaceutical company’s stock valued at $377,000 after purchasing an additional 1,158 shares in the last quarter. Finally, Kingsview Wealth Management LLC increased its holdings in shares of Gilead Sciences by 110.9% in the fourth quarter. Kingsview Wealth Management LLC now owns 42,014 shares of the biopharmaceutical company’s stock worth $3,881,000 after purchasing an additional 22,091 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock valued at $53,611,715 over the last ninety days. 0.16% of the stock is owned by company insiders.

Gilead Sciences Trading Up 0.7 %

Shares of NASDAQ GILD opened at $96.14 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $100.51. The firm has a market cap of $119.82 billion, a PE ratio of 1,068.22, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The business has a fifty day simple moving average of $93.07 and a two-hundred day simple moving average of $86.99. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Analysts expect that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research reports. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $87.00 to $113.00 in a research note on Friday, January 10th. Barclays raised their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Truist Financial lifted their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Finally, Citigroup began coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.